Please login to the form below

Not currently logged in
Email:
Password:

Potential blood cancer treatment tested

Immune System Therapeutics has launched a clinical trial to test its breakthrough treatment for terminal blood cancers

Immune System Therapeutics Ltd (IST) has launched a clinical trial to test its breakthrough treatment for terminal blood cancers.

The Australian medical research company has genetically engineered an antibody drug that binds specifically to a target protein found on the surface of some blood cancer cells. Laboratory studies, using cells taken from patients with a type of blood cancer called multiple myeloma, have shown that the antibody works with the human immune system to induce death of the cancer cells. It is anticipated that the antibody will potentially reduce the number of cancerous cells in multiple myeloma patients and improve patient health and wellbeing.

IST has commenced a Phase 1 trial in patients with multiple myeloma and to date six patients have been treated at The Alfred Hospital in Melbourne. Results so far indicate that the antibody has no side effects and final results are expected later this year.

20th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...
How Helpful are Simple Health Messages?
...

Infographics